NHS Watchdog Rejects Mounjaro Fat Loss Jab for Diabetes Due to Cost Concerns

NICE Withholds Recommendation for Mounjaro Weight Loss Injection on NHS
The UK's National Institute for Health and Care Excellence (NICE) has rejected the recommendation of the Mounjaro fat loss jab, a new diabetes medicine, for NHS use due to concerns about its cost-effectiveness. NICE has requested more evidence on Mounjaro, despite recently approving a similar weight loss injection called Wegovy. Both drugs help reduce appetite and manage blood glucose levels. The demand for such treatments has increased due to social media posts featuring celebrities losing significant amounts of weight. NICE's draft guidelines state that more evidence is needed to determine if Mounjaro represents good value for money compared to diet and exercise for adults with type 2 diabetes and high body mass index. The manufacturer, Eli Lilly, has been asked to provide additional data for evaluation. The recommendation does not impact those already receiving tirzepatide treatment before the guidance was issued. Wegovy, on the other hand, has been approved for NHS use in England for adults with obesity-related health issues, including type 2 diabetes.

Latest Posts